Rapido's $240M at $3B: Prosus Doubles Down on India's Mobility Leader
India's Rapido raised $240M at a $3B valuation in May 2026, led by Prosus, as part of a $730M financing to defend its lead in two-wheeler mobility against Uber.
Venture Capital News, Guides & Fund Directory
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
What You'll Find Here
- Fund profiles & directories: Stage focus, sector thesis, and check-size context for active investors
- Deal flow analysis: Funding roundups, mega-rounds, and emerging-manager activity
- Founder playbooks: Pitch decks, term sheets, warm intros, and fundraising strategy
- Market intelligence: Sector trends, valuation shifts, and LP allocation patterns
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
Related Articles (326 articles)
Gaingels Crosses $1B Deployed, Wins NVCA Inclusion Award
Gaingels, the LGBTQ+/allies venture syndicate, crossed $1B deployed across 2,600+ rounds and won the NVCA 2026 Inclusion Impact Award.
Sarvam AI's $350M at $1.5B: India's Sovereign Foundation-Model Unicorn
Bengaluru's Sarvam AI reached a $1.5B valuation in 2026 with a ~$350M round backed by HCLTech, Nvidia, and Amazon — India's flagship sovereign-AI bet.
Anduril's $5B Series H: Defense Tech's Valuation Doubles to $61B
Anduril raised $5B at a $61B valuation in May 2026, led by Thrive Capital and a16z — more than doubling its mark in a year and cementing defense tech as a core venture category.
Cowboy Ventures Backs Basata $21M Series A for Healthcare Ops
Cowboy Ventures joined Basata’s $21M Series A to automate healthcare operations, part of a busy 2026 that also included leading Petual’s seed round.
Anagram Therapeutics's $250M: A Big Biotech Bet Amid AI's Spotlight
Anagram Therapeutics raised $250M in May 2026, one of the largest biotech rounds of the period, proving life-sciences capital is alive alongside AI.